Preparation method and application of supramolecular solvent containing puerarin

Abstract

This invention relates to the field of cosmetic technology, specifically to a method for preparing and applying a supramolecular solvent containing puerarin. The supramolecular solvent containing puerarin comprises: puerarin, a hydrogen bond donor, and a hydrogen bond acceptor; the molar ratio of the hydrogen bond donor to the acceptor is 1-3:1-2. This invention utilizes a supramolecular solvent containing puerarin formed by weak interactions such as hydrogen bonds, which can effectively solve problems such as easy precipitation of puerarin in products and poor transdermal absorption. Simultaneously, this supramolecular solvent containing puerarin can synergistically enhance the effect of puerarin in oil-controlling and acne-reducing products. Cosmetics made using the supramolecular solvent prepared by this invention have good oil-controlling and soothing effects, and the preparation process is simple, easy to scale up, and has stable properties.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to a method for preparing and applying a supramolecular solvent containing puerarin. Background Technology

[0002] Puerarin is an isoflavone compound extracted from kudzu root, possessing significant anti-inflammatory, antioxidant, and sebum metabolism-regulating activities. Puerarin reduces the inflammatory response caused by Propionibacterium acnes by inhibiting the release of inflammatory factors. Simultaneously, its antioxidant effect reduces follicular blockage caused by sebum oxidation, thereby preventing acne formation. Furthermore, puerarin indirectly controls sebum production by regulating pathways such as PPARγ to inhibit excessive sebum secretion. However, traditional puerarin formulations have poor water and lipid solubility, resulting in insufficient bioavailability.

[0003] Acne vulgaris, a chronic inflammatory skin disease, involves multiple interacting factors in its pathogenesis, including abnormal keratinization of the pilosebaceous duct, excessive proliferation of Propionibacterium acnes, hypersecretion of sebum, and dysregulation of the inflammatory response. Therefore, it has long troubled many people. According to a World Health Organization survey, more than 1 billion people worldwide suffer from acne, with a prevalence rate as high as 85% among adolescents. While current treatments can alleviate acne, they still face challenges such as drug resistance and high skin irritation.

[0004] For the treatment of acne, acids remain a commonly used and effective treatment method in both clinical practice and cosmetic science. Mandelic acid and salicylic acid, as classic hydroxy acids, have long been widely used in skin care due to their unique lipid solubility and keratin-regulating properties, especially in oil control and acne treatment. However, the application of traditional hydroxy acids in skin care has significant limitations, such as the poor solubility and high irritation of salicylic acid, and the difficulty in transdermal absorption of mandelic acid. Therefore, how to simultaneously address the limitations of hydroxy acid solubility remains a hot topic in the field of skin care.

[0005] For example, Chinese patent CN112375075A discloses a method for extracting puerarin using a natural eutectic solvent. The method involves adding kudzu root powder to an aqueous solution of a natural eutectic solvent, ultrasonically extracting at 20-75℃ and 200W for 15-75 minutes, centrifuging, and collecting the supernatant to obtain a kudzu root extract containing puerarin. The natural eutectic solvent in the aqueous solution is a mixture of a hydrogen bond donor and a hydrogen bond acceptor and / or deionized water. This invention provides a highly efficient and environmentally friendly method for extracting puerarin using a natural eutectic solvent, achieving an extraction rate 79.2% higher than that of water extracts. This method features short extraction time, low energy consumption, and is environmentally friendly. This invention, by introducing a natural eutectic solvent for puerarin extraction, provides a new research and development approach for the extraction of active ingredients from traditional Chinese medicine.

[0006] For example, Chinese patent CN117682949A discloses a deep eutectic solvent for salicylic acid, its preparation method, and its application. This deep eutectic solvent for salicylic acid is formed by the combination of salicylic acid, L-carnitine, and optional polyols under intermolecular forces. This alters the molecular polarity of the deep eutectic solvent for salicylic acid, enhances the hydrogen bonding and van der Waals forces with water, increases the water solubility of salicylic acid, and improves the transdermal permeability of L-carnitine and salicylic acid. Skin care products and toiletries made from this solvent require minimal additives, have a pleasant feel, and are gentle and non-irritating. The preparation method provided by this invention integrates multiple deep eutectic solvent preparation methods, with mild reaction conditions, short reaction time, and suitability for industrial production. Furthermore, the reaction is thorough, simultaneously improving the availability of multiple substances.

[0007] Therefore, there is an urgent need to study a method that can improve the problems of poor solubility, easy precipitation, and difficulty in transdermal absorption of puerarin, while being safe and non-irritating. Summary of the Invention

[0008] In view of the shortcomings of the existing technology, the present invention aims to provide a method for preparing and applying a supramolecular solvent containing puerarin.

[0009] To achieve the above-mentioned technical objectives, the present invention is implemented through the following technical solution:

[0010] On one hand, the present invention provides a supramolecular solvent containing puerarin, comprising: puerarin, a hydrogen bond donor, and a hydrogen bond acceptor.

[0011] Preferably, the hydrogen bond donor is at least two of glycerol, glucose, butylene glycol, propylene glycol, salicylic acid, mandelic acid, and malic acid;

[0012] More preferably, the hydrogen bond donor is glycerol and salicylic acid or glycerol and mandelic acid.

[0013] Preferably, the hydrogen bond acceptor is at least one of betaine, choline chloride, and carnitine;

[0014] More preferably, the hydrogen bond acceptor is betaine or carnitine.

[0015] Preferably, the molar ratio of the hydrogen bond donor to the acceptor is 1-3:1-2.

[0016] Preferably, the mass percentage of puerarin in the supramolecular solvent is 5%-10%, more preferably 9%-10%, and even more preferably 9.09%.

[0017] On the other hand, the present invention also provides a method for preparing the above-mentioned supramolecular solvent containing puerarin, comprising the following steps:

[0018] (1) Weigh out the hydrogen bond donor and hydrogen bond acceptor and mix them thoroughly;

[0019] (2) Under the protection of an inert gas, heat and stir until homogeneous to obtain a mixed solution;

[0020] (3) Under the protection of inert gas, add an ethanol solution of puerarin to the mixed solution obtained in step (2), heat and stir, sonicate, and cool to obtain the final product.

[0021] Preferably, the inert gas in step (2) is one of helium, argon or nitrogen, preferably argon.

[0022] Preferably, the pressure of the inert gas in step (2) is 5-20 MPa, and more preferably 10 MPa.

[0023] Preferably, the heating and stirring temperature in step (2) is 30-100℃, the heating and stirring speed is 50-200rpm, and the heating and stirring time is 18-24h.

[0024] More preferably, the heating and stirring temperature in step (2) is 85°C, the heating and stirring speed is 200 rpm, and the heating and stirring time is 18 h.

[0025] Preferably, the ultrasonic treatment in step (3) has a power of 200-600W and a frequency of 10-30kHz, with a 5s pause and a duration of 1-3h.

[0026] More preferably, the ultrasonic treatment in step (3) has a power of 200W and a frequency of 20kHz, with ultrasound for 5 seconds followed by a 5-second pause, and continues for 2 hours.

[0027] Preferably, the amount of ethanol added to puerarin in step (3) is 5-10 mL, and more preferably 9 mL.

[0028] Finally, this invention also provides the application of the above-mentioned supramolecular solvent containing puerarin in the preparation of oil-controlling and acne-removing products.

[0029] Preferably, the product is a cosmetic or a pharmaceutical.

[0030] Preferably, the cosmetic product is an acne treatment lotion, acne treatment essence, or acne treatment cream.

[0031] Preferably, the product contains 0.1%-5% by mass of the supramolecular solvent of puerarin.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] This invention utilizes a hydrogen bond acceptor and a hydrogen bond donor in a specific ratio to generate weak intermolecular interactions such as hydrogen bonds and van der Waals forces with puerarin. Simultaneously, the hydrogen bond donor contains hydroxy acids such as salicylic acid, significantly improving the poor solubility, easy precipitation, and difficulty in transdermal absorption of puerarin and hydroxy acids. Furthermore, the supramolecular solvent contains a large hydrogen bond network, encapsulating the puerarin molecules and further reducing skin irritation caused by the burst release of puerarin and hydroxy acids into the product. In terms of preparation, this invention is simple to prepare and can be mass-produced, laying the foundation for the application of aqueous puerarin in pharmaceuticals and skin care. Attached Figure Description

[0034] Figure 1 The supramolecular solvent prepared in the basic example 1 of this invention 1 HNMR spectrum (horizontal axis: chemical shift f1 (ppm), vertical axis: absorption intensity);

[0035] Figure 2 The supramolecular solvent prepared in the basic example 2 of this invention 1 HNMR spectrum (horizontal axis: chemical shift f1 (ppm), vertical axis: absorption intensity);

[0036] Figure 3 This is a statistical chart showing the toxic effects of the puerarin-containing supramolecular solvent prepared in Example 1 of this invention on HaCat cells.

[0037] Figure 4 This is a statistical chart showing the toxic effects of the puerarin-containing supramolecular solvent prepared in Example 1 of this invention on RAW 264.7 cells;

[0038] Figure 5 This is a graph showing the cumulative permeation amount in the in vitro transdermal diffusion experiment of the supramolecular solvent containing puerarin prepared in Example 1 of the present invention and ordinary puerarin.

[0039] Figure 6 This is an experimental diagram showing the effect of the puerarin-containing supramolecular solvent prepared in Example 1 of the present invention on the IL-8 content;

[0040] Figure 7This is an experimental diagram showing the effect of the supramolecular solvent containing puerarin prepared in Example 1 of this invention on the IL-1α content;

[0041] Figure 8 The figure shows the effect of the supramolecular solvent containing puerarin prepared in Example 1 of this invention on the TNF-α content.

[0042] Figure 9 This is a cell counting diagram of HaCat cells after exfoliation using a supramolecular solvent containing puerarin prepared in Example 1 of this invention.

[0043] Figure 10 This is an experimental diagram showing the effect of the supramolecular solvent containing puerarin prepared in Example 1 of the present invention on the synthesis of lipids in SZ95 cells induced by linoleic acid. Detailed Implementation

[0044] The technical solution of the present invention will be clearly and completely described below with reference to specific embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention. Unless otherwise specified, the materials and reagents used are commercially available.

[0045] Basic Example 1: Preparation of supramolecular solvents with mandelic acid groups

[0046] The specific operating steps are as follows:

[0047] (1) Take mandelic acid, betaine and water in a molar ratio of 1:1:3, totaling 100g, and mix them evenly.

[0048] (2) Under the protection of argon gas at a pressure of 10 MPa, the temperature is raised to 85°C and stirred until there is no obvious layering;

[0049] (3) Ultrasonic treatment with a power of 200W, an ultrasonic frequency of 20kHz, and a treatment time of 2h yields a colorless to pale yellow transparent liquid.

[0050] according to Figure 1 As shown, no covalent bonds are generated in the resulting liquid; only weak interactions such as hydrogen bonds and van der Waals forces between molecules promote the formation of supramolecular solvents.

[0051] Basic Example 2: Preparation of Supramolecular Solvents with Salicylic Acid Groups

[0052] The specific operating steps are as follows:

[0053] (1) Take salicylic acid, carnitine, glycerin and water in a molar ratio of 1:2:2:6, totaling 100g, and mix them evenly;

[0054] (2) Under the protection of argon gas at a pressure of 10 MPa, the temperature is raised to 85°C and stirred until there is no obvious layering;

[0055] (3) Ultrasonic treatment with a power of 200W, an ultrasonic frequency of 20kHz, and a treatment time of 2h yields a light yellow transparent liquid.

[0056] according to Figure 2 As shown, no covalent bonds are generated in the resulting liquid; only weak interactions such as hydrogen bonds and van der Waals forces between molecules promote the formation of supramolecular solvents.

[0057] Example 1: Preparation of a supramolecular solvent containing puerarin

[0058] The specific operating steps are as follows:

[0059] (1) Take salicylic acid, carnitine, glycerin and water in a molar ratio of 1:2:2:6, totaling 100g, and mix them evenly;

[0060] (2) Under the protection of argon gas at a pressure of 10 MPa, the temperature is raised to 85°C and stirred until there is no obvious layering;

[0061] (3) In an argon atmosphere, add 9 mL of puerarin ethanol solution, turn on the argon flow, heat and stir until the solution is transparent and clear; use ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h.

[0062] (4) Detect the amount of ethanol residue, and after the ethanol residue is gone, cool down to obtain a supramolecular solvent containing 9.09% puerarin by mass.

[0063] Example 2: Preparation of a supramolecular solvent containing puerarin

[0064] The specific operating steps are as follows:

[0065] (1) Take mandelic acid, betaine and water in a molar ratio of 1:1:3, totaling 100g, and mix them evenly.

[0066] (2) Under the protection of argon gas at a pressure of 10 MPa, the temperature is raised to 85°C and stirred until there is no obvious layering;

[0067] (3) In an argon atmosphere, add 9 mL of puerarin ethanol solution, turn on the argon flow, heat and stir until the solution is transparent and clear; use ultrasonic treatment with a power of 200 W, an ultrasonic frequency of 20 kHz, and a treatment time of 2 h.

[0068] (4) Detect the amount of ethanol residue, and after the ethanol residue is gone, cool down to obtain a supramolecular solvent containing 9.09% puerarin by mass.

[0069] Comparative Example 1

[0070] The difference from Example 1 is that the molar ratio of salicylic acid, carnitine, glycerol and water is 1:3:3:3; after cooling and dilution with water, a large amount of solid precipitates out, proving that the supramolecular solvent is not stable.

[0071] Comparative Example 2

[0072] The difference from Example 2 is that the molar ratio of mandelic acid, betaine and water is 4:1:3; after cooling and dilution with water, a large amount of solid precipitates out, proving that the supramolecular solvent is not stable.

[0073] Comparative Example 3

[0074] The only difference from Example 1 is that room temperature stirring was used in step (2); it was found that after stirring for 18 hours, there were still a lot of solid particles in it, and a uniform and transparent supramolecular solvent was not formed.

[0075] Comparative Example 4

[0076] The only difference from Example 1 is that ultrasonic treatment is not performed in step (3); the results showed that the sample became turbid after 24 hours and began to separate into layers, and did not have long-term stability.

[0077] Application Example 1: Preparation of an acne-removing essence containing puerarin supramolecular solvent

[0078] (1) Add 1% glycerol, 3% butanediol, 0.5% p-hydroxyacetophenone, 0.6% hexanediol, 0.05% sodium acrylate copolymer, 0.05% sodium hyaluronate, 2% Tween-60 and the remainder water to a 200g beaker and heat at 80℃ for 20min.

[0079] (2) Add 2.5% squalane, 2% polyglycerol-3-methylglucose distearate, 0.5% jojoba seed oil and 0.3% cetearyl alcohol by mass, homogenize at 7000 rpm for 3 min, and stir to cool.

[0080] (3) When the temperature of the material drops to 45°C, add 1% by mass of the supramolecular solvent containing puerarin prepared in Example 1 and the remainder water, and then cool down to obtain the final product.

[0081] Application Example 2: Preparation of Acne Treatment Lotion Containing Puerarin and Salicylic Acid Supramolecular Solvents

[0082] (1) Add 3% glycerol, 5% butanediol, 0.5% p-hydroxyacetophenone, 0.6% hexanediol, 0.05% sodium hyaluronate, 0.1% EDTA-2Na and the remainder water to a 200g beaker and heat at 80℃ for 20min.

[0083] (2) Homogenize at 7000 rpm for 3 min, then stir and cool.

[0084] (3) When the temperature of the material drops to 45°C, add 1% by mass of the supramolecular solvent containing puerarin prepared in Example 1 and the remainder water; cool down to obtain the final product.

[0085] Application Example 3: Preparation of an acne cream containing puerarin and salicylic acid supramolecular solvents

[0086] (1) Add 0.2% carbomer 940, 5% glycerol, 0.05% xanthan gum, 0.5% hexanediol, 0.5% p-hydroxyacetophenone, 0.05% sodium hyaluronate, 0.1% EDTA-2Na and the remainder water to a 200g beaker and heat at 80℃ for 20min.

[0087] (2) Add 6% isohexadecane, 2% shea butter, 1.5% C16-18 alcohol, 2% glyceryl stearate, and 0.5% PEG-100 stearate by mass fraction, homogenize at 9000 rpm for 5 min, and then stir and cool.

[0088] (3) When the temperature of the material drops to 45°C, add 0.15% arginine and 1% supramolecular solvent containing puerarin prepared in Example 1 and the remainder water, and then cool down to obtain the final product.

[0089] Effect Experiment

[0090] 1. Supramolecular solvent cytotoxicity of puerarin-containing compounds

[0091] The effect of supramolecular solvents containing puerarin on the cytotoxicity of HaCaT and RAW 264.7 cells was determined by MTT assay: HaCaT or RAW 264.7 cells were used at a cell density of 8000 cells / cm³. 2 Cells were seeded into 96-well plates. Different concentrations of the supramolecular solvent containing puerarin prepared in Example 1 and physical mixtures of puerarin-salicylic acid-carnitine-glycerol-water were co-cultured with HaCaT cells or RAW 264.7 cells for 48 h. MTT reagent was added, and the cells were incubated for 4 h. DMSO was then added, and the absorbance of each group of cells was measured at 490 nm to calculate the cell viability (%). Figure 3 , 4 As shown, the results indicated that the cell viability was no less than 85%, demonstrating that the supramolecular solvent containing puerarin had no cytotoxicity to HaCaT cells and RAW 264.7 cells, and that the cell safety was good.

[0092] The formula for calculating cell viability is as follows:

[0093]

[0094] Where A represents the absorbance value, the negative control group is the absorbance of cells that have not been treated with the drug, the blank control group is the absorbance of the 96-well plate itself, and the sample group is the absorbance of cells treated with the drug in Example 1.

[0095] 2. Cumulative permeation test of in vitro transdermal diffusion in supramolecular solvents containing puerarin and ordinary puerarin.

[0096] Exfoliated skin from undamaged Bama miniature pigs was cleaned with physiological saline and fixed to a Franz diffusion cell with the cuticle facing upwards. PBS was added to the receiving cell, and after equilibration for 30 minutes, air bubbles were removed by tapping with a rubber bulb. The water bath temperature was set to 32±1℃. 1g of the supramolecular solvent containing puerarin prepared in Example 1 was accurately weighed. The receiving cell was stirred at 600 rpm, and samples were collected at 2h, 4h, 6h, 8h, 10h, 12h, and 24h. The samples were centrifuged at 12000 rpm for 10 minutes, and the supernatant was collected. After filtering through a 0.22μm filter membrane, liquid chromatography was performed, and the cumulative permeate was calculated. Figure 5 As shown. The diffusion cell has an opening diameter of 20 mm, and the effective diffusion surface area is approximately 3.14 cm. 2 .

[0097] The formula for calculating cumulative transmittance is as follows:

[0098]

[0099] Among them, Q n The cumulative permeation is V, where V is the total volume of the receiving liquid, and C is the total volume of the receiving liquid. n C represents the drug concentration in the receiving solution during the nth sampling. i V represents the mass concentration of the drug in the receiving solution during the i-th sampling. i Where A is the sampling volume and A is the effective diffusion area.

[0100] 3. Effects of supramolecular solvents containing puerarin on cellular inflammatory factors.

[0101] RAW264.7 cells in logarithmic growth phase with good morphology were seeded in 24-well plates at a cell density of 2 × 10⁶ cells per well. 5 pcs / cm 2 A blank control group, a stimulation group, and a sample group were set up and incubated at 37°C in a 5% CO2 incubator for 12 h. Except for the blank control group, lipopolysaccharide (LPS) was added to each well for stimulation and induction. Different concentrations of supramolecular solvent containing puerarin prepared in Example 1 were added to the sample group, and incubation was carried out for 24 h. The contents of IL-1α, TNF-α, and IL-8 in the collected cell supernatant were detected, and the inhibition rate of inflammatory factors in each group relative to the LPS-induced stimulation group was calculated. The results are as follows: Figure 6 , 7 As shown in Figures 8 and 9. The results show that, within a safe concentration range, supramolecular solvents containing puerarin have a significant inhibitory effect on cellular inflammatory factors.

[0102] 4. The effect of supramolecular solvents containing puerarin on the cell counting of exfoliated HaCaT cells.

[0103] HaCaT cells in logarithmic growth phase with good morphology were seeded into 6-well plates at a cell density of 10-1 per well. 6 Cells / well. A blank control group and Example 1 group were set up and incubated at 37°C in a 5% CO2 incubator for 12 hours. Except for the blank control group, different concentrations of supramolecular solvent containing puerarin were added to each well for incubation for 12 hours. Cell supernatant was collected, and the number of exfoliated keratinocytes was determined using a cell counter. Figure 9 As shown, the results indicate that, within a safe concentration range, supramolecular solvents containing puerarin have an exfoliating effect on HaCaT cells.

[0104] 5. Irritation test of supramolecular solvent skin patches containing puerarin

[0105] Using qualified patch testing equipment and a closed patch test method, the supramolecular solvent containing puerarin prepared in Example 1 was diluted with purified water to a concentration of 3% as the sample group. Purified water was used as the negative control group. Approximately 0.020g-0.025g of each sample was placed in the patch testing device and applied externally with hypoallergenic adhesive tape to the inner arm of 32 subjects (aged 22-39, healthy). The test substance was removed after 24 hours, and skin reactions were observed at 0.5, 24, 48, and 72 hours after removal. The results were recorded according to the skin reaction grading standards in the "Cosmetic Safety Technical Specifications" (2015 edition). The results are shown in Tables 1 and 2. The results show that in the human patch test, the 3% supramolecular solvent containing puerarin did not cause adverse skin reactions and had low irritation.

[0106] Table 1

[0107]

[0108] Table 2

[0109]

[0110]

[0111] 6. Effects of supramolecular solvents containing puerarin on linoleic acid-induced lipid secretion in SZ95 cells.

[0112] SZ95 cells in logarithmic growth phase with good morphology were seeded into 96-well plates at a cell density of 8000 cells / cm².2 A blank control group and a sample group were set up and incubated at 37°C in a 5% CO2 incubator for 12 hours. Except for the blank control group, linoleic acid was added to each well for stimulation and induction. Different concentrations of the supramolecular solvent containing puerarin prepared in Example 1 were added to the sample group, and incubation was carried out for 24 hours. Nile red reagent was added for further incubation, and fluorescence intensity was measured using a multi-functional microplate reader. Figure 10 As shown in the results, the fluorescence intensity of the sample group with added supramolecular solvent containing puerarin decreased significantly, proving that the supramolecular solvent containing puerarin can inhibit linoleic acid-induced lipid synthesis in SZ95 cells and has a good oil-controlling effect.

[0113] 7. Stability Test

[0114] Test sample: The sample prepared in Example 1.

[0115] Experimental methods:

[0116] The test samples were subjected to five conditions for 15 days, 30 days, 60 days, and 90 days: -18℃, room temperature, light exposure, 45℃, and a thermal cycling test between -18℃ and 45℃ (12 hours at -18℃ and 12 hours at 45℃). No significant changes were observed in each sample; no change was considered acceptable, while changes were considered unacceptable. The test results are shown in Table 3. As can be seen from Table 3, the supramolecular solvent containing puerarin prepared in Example 1 showed no significant changes in appearance, pH, or color during the 90-day stability test, demonstrating good stability.

[0117] Table 3

[0118]

[0119]

[0120] The above detailed description is a specific description of one of the feasible embodiments of the present invention. This embodiment is not intended to limit the patent scope of the present invention. All equivalent implementations or modifications that do not depart from the present invention should be included within the scope of the technical solution of the present invention.

Claims

1. A supramolecular solvent containing puerarin, characterized in that, include: Puerarin, hydrogen bond donor, and hydrogen bond acceptor; the molar ratio of the hydrogen bond donor and acceptor is 3:2; The hydrogen bond donors are salicylic acid and glycerol, and the hydrogen bond acceptor is carnitine; The salicylic acid, carnitine, and glycerol are in a molar ratio of 1:2:

2. The method for preparing the supramolecular solvent includes the following steps: (1) Weigh out the hydrogen bond donor and hydrogen bond acceptor and mix them thoroughly; (2) Under the protection of an inert gas, heat and stir until homogeneous to obtain a mixed solution; (3) Under the protection of inert gas, add an ethanol solution of puerarin to the mixed solution obtained in step (2), heat and stir, sonicate, and cool to obtain the final product; The inert gas mentioned in step (2) is one of helium, argon or nitrogen; the pressure of the inert gas is 5-20 MPa; The heating and stirring temperature in step (2) is 85°C, the heating and stirring speed is 50-200 rpm, and the heating and stirring time is 18-24 h; The ultrasonic treatment in step (3) has a power of 200-600W, a frequency of 10-30kHz, and lasts for 1-3 hours; The puerarin in the supramolecular solvent accounts for 5%-10% by mass fraction.

2. The application of the supramolecular solvent according to claim 1 in the preparation of oil-controlling and acne-removing products.

3. The application according to claim 2, characterized in that, The product in question is a cosmetic or a pharmaceutical.

Images